Financing ·
Aptevo Therapeutics Inc. closed a financing transaction on August 13, 2026, raising approximately $4.5 million in…
APVOAptevo Therapeutics Inc.
Aptevo Therapeutics Inc. closed a financing transaction on August 13, 2026, raising approximately $4.5 million in gross proceeds for working capital and general corporate purposes. The company entered into warrant inducement letters with holders of existing warrants issued between December 2024 and June 2025, requiring the exercise of up to 254,922 warrants at a reduced price of $4.03 per share. In exchange for these exercises, Aptevo issued new unregistered warrants (Inducement Warrants) to purchase up to 1,274,610 shares at $4.03 per share, exercisable after stockholder approval and expiring five years later. Simultaneously, the company sold up to 861,708 shares of common stock (or pre-funded warrants) in a private placement PIPE at $4.03 per share, accompanied by Common Warrants to purchase up to 4,308,540 additional shares at the same exercise price. Roth Capital Partners acted as the exclusive placement agent for a 7% fee plus expense reimbursement. Aptevo Therapeutics Inc. is a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics.